|Bid||163.58 x 800|
|Ask||163.60 x 900|
|Day's Range||162.68 - 164.06|
|52 Week Range||148.99 - 179.92|
|Beta (5Y Monthly)||0.70|
|PE Ratio (TTM)||28.92|
|Earnings Date||Jan 25, 2022|
|Forward Dividend & Yield||4.24 (2.56%)|
|Ex-Dividend Date||Aug 23, 2021|
|1y Target Est||187.17|
Yahoo Finance anchors discuss a rise in vaccine stocks as Pfizer and Moderna rise amid Omnicron news.
New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.
In this segment of Backstage Pass, recorded on Nov. 12, Fool contributors Toby Bordelon and Rachel Warren share their thoughts on the breakup trend, including on the planned split recently announced by pharmaceutical giant Johnson & Johnson (NYSE: JNJ). Toby Bordelon: One bit of news we did have this week is there have been a lot of breakups, it seems like, that were announced this week.